Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07084311 · ClinicalTrials.gov registry record · Phase 1
Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation
A Phase 1 study of Dentatorubral-Pallidoluysian Atrophy, sponsored by n-Lorem Foundation.
- Active
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT07084311 is a Phase 1 study of Dentatorubral-Pallidoluysian Atrophy that is active but no longer recruiting, run by n-Lorem Foundation. The registered enrollment target is 1 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07084311, a Phase 1 study of Dentatorubral-Pallidoluysian Atrophy, is active but no longer recruiting, sponsored by n-Lorem Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with dentatorubral-pallidoluysian atrophy (DRPLA) due to a heterozygous pathogenic CAG trinucleotide expansion in ATN1
Conditions Studied
Interventions
- DRUG nL-ATN1-002
Study Locations (1)
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-10-24 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07084311
The ClinicalTrials.gov registry entry for NCT07084311 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is n-Lorem Foundation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dentatorubral-Pallidoluysian Atrophy appearing as the primary indexed condition, and to 1 intervention - of which nL-ATN1-002 is the first listed.
NCT07084311 reports 1 study location spanning 1 distinct geographic area - top geographies include Hawaii.
Frequently Asked Questions
What is clinical trial NCT07084311 about?
NCT07084311 is a clinical study titled "Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation". This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with dentatorubral-pallidoluysian atrophy (DRPLA) due to a heterozygous pathogenic CAG trinucleotide expansion in ATN1
What is the current status of trial NCT07084311?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-10-24. Estimated completion is 2026-11.
What conditions does trial NCT07084311 study?
This clinical trial studies the following conditions: Dentatorubral-Pallidoluysian Atrophy.
What interventions are being tested in trial NCT07084311?
The interventions under investigation include: nL-ATN1-002 (DRUG).
Who is sponsoring clinical trial NCT07084311?
This trial is sponsored by n-Lorem Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07084311 being conducted?
This trial has 1 study location across Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dentatorubral-Pallidoluysian Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.